GlassScriptPhysician profile
Mollie M Doty
NPI 1457398729
$12,302.61
in general payments reported to CMS, 2019-2025
33 companies · $2,889 in 2025
The $2,889 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,088 · 2022: $2,559 · 2023: $2,533 · 2024: $2,234 · 2025: $2,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,475 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,475.36 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,761.27 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,504.45 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Actelion Pharmaceuticals US, INC. | $1,056.02 | 2021-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $995.44 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Mallinckrodt Hospital Products INC. | $810.17 | 2021-2025 | Acthar |
| Genzyme Corporation | $721.55 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $615.78 | 2021-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $457.74 | 2021-2025 | |
| Mylan Specialty L.P. | $452.07 | 2022-2024 | Yupelri |
| United Therapeutics Corporation | $317.32 | 2021-2025 | Tyvaso, Tyvaso, Remodulin |
| Takeda Pharmaceuticals U.S.A., INC. | $312.01 | 2021-2025 | Glassia |
| Janssen Pharmaceuticals, INC | $288.38 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $204.12 | 2022-2025 | Zerbaxa, Winrevair, Recarbrio |
| Bayer Healthcare Pharmaceuticals INC. | $196.06 | 2021-2025 | |
| Genentech USA, INC. | $176.49 | 2021-2023 | Xolair |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $174.37 | 2025 | Yupelri |
| Insmed, INC. | $157.30 | 2021-2025 | Arikayce |
| Verona Pharma, INC. | $143.40 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $138.47 | 2022-2023 | Sunosi |
| Pfizer INC. | $127.73 | 2022-2025 | |
| Inspire Medical Systems, INC. | $109.87 | 2023 | Inspire |
| Baxter Healthcare | $100.94 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Ani Pharmaceuticals, INC. | $91.85 | 2023-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $84.12 | 2021-2023 | Eliquis |
| Electromed, INC. | $69.45 | 2024-2025 | Smartvest |
| Advanced Respiratory, INC | $61.57 | 2021 | |
| Philips North America LLC | $42.52 | 2021 | |
| Ibsa Pharma INC. | $35.89 | 2021 | |
| Liquidia Technologies, INC. | $35.64 | 2025 | Yutrepia |
| Mayne Pharma Commercial LLC | $18.34 | 2022 | |
| Amgen INC. | $15.47 | 2025 | Tezspire |
| Gilead Sciences, INC. | $13.49 | 2021 | |
| Nabriva Therapeutics, Plc | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mollie Doty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.